276 related articles for article (PubMed ID: 29793418)
1. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
2. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S53-S57. PubMed ID: 31253514
[TBL] [Abstract][Full Text] [Related]
3. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
Jurcic JG; Rosenblat TL
Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
5. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
[TBL] [Abstract][Full Text] [Related]
6. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
Semin Nucl Med; 2020 Mar; 50(2):152-161. PubMed ID: 32172800
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Rosenblat TL; McDevitt MR; Carrasquillo JA; Pandit-Taskar N; Frattini MG; Maslak PG; Park JH; Douer D; Cicic D; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2022 May; 28(10):2030-2037. PubMed ID: 35247915
[TBL] [Abstract][Full Text] [Related]
8. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
Radchenko V; Schaffer P; Knapp FFR
Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
[No Abstract] [Full Text] [Related]
10. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
[TBL] [Abstract][Full Text] [Related]
11. Development of
Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
[TBL] [Abstract][Full Text] [Related]
12. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
13. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
14. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
15. Alpha-particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment.
Featherstone C
Mol Med Today; 1997 Jun; 3(6):232-3. PubMed ID: 9211409
[No Abstract] [Full Text] [Related]
16. NorthStar Perspectives for Actinium-225 Production at Commercial Scale.
Harvey JT
Curr Radiopharm; 2018; 11(3):180-191. PubMed ID: 29766832
[TBL] [Abstract][Full Text] [Related]
17. Antibody therapy of acute myelogenous leukemia.
Jurcic JG
Cancer Biother Radiopharm; 2000 Aug; 15(4):319-26. PubMed ID: 11041016
[TBL] [Abstract][Full Text] [Related]
18. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
19.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
20.
Jiang Z; Revskaya E; Fisher DR; Dadachova E
Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]